A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
September 15, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
May 31, 2028
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions
BIOLOGICAL
QLS32015
QLS32015 is a GPRC5D × CD3 bispecific antibody.
All Listed Sponsors
lead
Institute of Hematology & Blood Diseases Hospital, China
OTHER
NCT07185477 - A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter